Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Over-the-Counter OTC | Nonprescription Drugs

Over-the-Counter OTC | Nonprescription Drugs

                        The FDA Announces Proposed Rule: Nonprescription Drug Product with an Additional Condition for Nonprescription Use
          Over-the-Counter (OTC) Drug Review | OTC Monograph Reform  in the CARES Act


                        Historical Status of OTC Rulemakings Home
          Drugs
          Development & Approval Process | Drugs
          How Drugs are Developed and Approved
          Over-the-Counter OTC | Nonprescription Drugs
          Over-the-Counter (OTC) Drug Review | OTC Monograph Reform  in the CARES ActOver-the-Counter OTC | Nonprescription Drugs Over-the-Counter (OTC) Drug Review | OTC Monograph Reform  in the CARES Act
  
  					Information about Over-the-Counter (OTC) Monograph Reform
	
    Share
    Post
    Linkedin

    Email
    PrintAbout OTC Monograph Reform

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) (Public Law No. 116-136, 134 Stat. 281, 457) was signed into law. The CARES Act includes provisions that govern the way certain OTC drugs are regulated in the United States. The CARES Act added section 505G to the Federal Food, Drug and Cosmetic Act (FD&C Act (21 U.S.C. 355g). Section 505G reforms and modernizes the OTC drug review process.

OTC Drug Review Process | OTC Monographs

OTC monograph drugs may be marketed without an approved drug application under section 505 of the FD&C Act if they meet the requirements of section 505G of the FD&C Act, including applicable conditions in an OTC monograph.

An OTC monograph establishes conditions, such as active ingredients, uses (indications), doses, routes of administration, labeling, and testing, under which an OTC drug in a given therapeutic category (e.g., sunscreen, antacid) is generally recognized as safe and effective (GRASE).

Under the process set forth in section 505G(b) of the FD&C Act, FDA has the authority to issue an administrative order (proposed and final) that adds, removes, or changes generally recognized as safe and effective (GRASE) conditions for an OTC drug monograph. Either FDA or a requestor can initiate the administrative order process.

For more information about the OTC Drug Review Process, see OTC Drug Review Process | OTC Drug Monographs.

OTC Monographs@FDA

OTC MONOGRAPHS @ FDA

OTC Monographs@FDA provides a resource for the public to view Administrative Orders (Proposed, Final, and Interim Final Orders) for OTC Monograph Drugs and view OTC Monographs. OTC Monographs@FDA also facilitates the ability for the public to submit, search, and view comments and data for Proposed and Interim Final Administrative Orders, except if otherwise specified.

OTC Monographs@FDA also provides resources and information about the regulation of OTC monograph drugs, including frequently asked questions, latest news, the annual forecast.

CDER NextGen Portal

FDA’s CDER NextGen Portal is a website for users to report information to FDA, including certain OTC monograph submissions. Sponsors and requestors of OTC monograph drugs are able to use the CDER NextGen Portal to submit requests for formal meetings with FDA and materials related to the formal meetings. Additionally, requestors can submit OTC Monograph order Requests (OMORs). In the future, sponsors and requestors will be able to submit other OTC monograph submissions via the CDER NextGen Portal, including formal dispute resolution requests related to a final administrative order, administrative hearing requests related to a final administrative order, and responses to record requests by FDA relating to minor changes.

Contact Us

**For questions on OTC monograph drugs or the OTC drug review process:**

Division of Drug Information (DDI) druginfo@fda.hhs.gov
	User fees CDERCollections@fda.hhs.gov
	Small business and industry assistance cdersbia@fda.hhs.govRelated Information

Office of Nonprescription Drugs
	OTC Monographs@FDA
	Over-The-Counter Monograph Drug User Fee Program

                                                                                  Content current as of:
      10/04/2023
              
              
Regulated Product(s)
		 Drugs
			  			     			  						              
			
			
			
			
						  Over-the-Counter DrugsOver-the-Counter OTC | Nonprescription Drugs

          
                        Proposed Rule: Nonprescription Drug Product with Additional Condition
          Over-the-Counter (OTC) Drug Review | OTC Monograph Reform  in the CARES Act


                        Historical Status of OTC Rulemakings
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop